BioXcel Therapeutics, Inc. (BTAI) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-06-18

BioXcel Therapeutics, Inc. (BTAI) has filed 12 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-18. 3 Form 8-K material event filings were reported by BTAI in the last 90 days. 4 Form 144 notices of proposed sale were filed for BTAI stock. InsiderAlpha tracks every BTAI SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About BioXcel Therapeutics, Inc. (BTAI)

SIC classification	Pharmaceutical Preparations (SIC 2834)
SEC CIK	0001720893

90-Day SEC Filing Activity

Form 4 filings (90d)	12
Form 8-K filings (90d)	3
Form 144 notices (90d)	4
Latest Form 4 filing	2026-06-18

Recent BTAI Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-06-15	Mehta Vimal	CEO and President	M — Option exercise	219	—	—	SEC
2026-06-15	Yocca Frank	Chief Scientific Officer	M — Option exercise	35	—	—	SEC
2026-06-15	Rodriguez Javier	See Remarks	M — Option exercise	35	—	—	SEC
2026-06-15	Steinhart Richard I	Chief Financial Officer	M — Option exercise	35	—	—	SEC
2026-05-20	Rodriguez Javier	See Remarks	S — Open-market sale	6.6K	$1.08	$7K	SEC
2026-05-20	Yocca Frank	Chief Scientific Officer	S — Open-market sale	6.8K	$1.08	$7K	SEC
2026-05-20	Steinhart Richard I	Chief Financial Officer	S — Open-market sale	6.8K	$1.08	$7K	SEC
2026-05-20	Mehta Vimal	CEO and President	S — Open-market sale	19.4K	$1.09	$21K	SEC
2026-05-04	Rodriguez Javier	See Remarks	M — Option exercise	17.5K	—	—	SEC
2026-05-04	Mehta Vimal	CEO and President	M — Option exercise	49.8K	—	—	SEC
2026-05-04	Steinhart Richard I	Chief Financial Officer	M — Option exercise	17.5K	—	—	SEC
2026-05-04	Yocca Frank	Chief Scientific Officer	M — Option exercise	17.5K	—	—	SEC
2026-05-01	Rodriguez Javier	See Remarks	M — Option exercise	9.0K	—	—	SEC
2026-05-01	Mehta Vimal	CEO and President	M — Option exercise	18.0K	—	—	SEC
2026-05-01	Steinhart Richard I	Chief Financial Officer	M — Option exercise	9.0K	—	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for BioXcel Therapeutics, Inc. (BTAI). Updated in real time as new filings are submitted to the SEC.

Most-Active BTAI Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Steinhart Richard I	7	$7K
Rodriguez Javier	7	$7K
Yocca Frank	7	$7K
Mehta Vimal	7	$21K

Recent BTAI Form 8-K Material Events

2026-07-06 — Item 1.01, 9.01 [SEC]
2026-05-15 — Item 2.02, 9.01 [SEC]
2026-04-17 — Item 3.02, 9.01 · Financing · negative [SEC]
BioXcel Therapeutics amended its credit agreement on April 15, 2026, granting lenders warrants to purchase 1,353,729 shares at $0.01 per share as consideration for the amendment. This dilutive warrant issuance signals financial stress and weak negotiating position, as the company
2026-04-01 — Item 8.01 · Clinical · positive [SEC]
BioXcel Therapeutics announced that the FDA has accepted its supplemental New Drug Application (sNDA) for IGALMI for the acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home (outpatient) setting. The FDA assigned a PDUFA target action date
2026-03-27 — Item 2.02, 9.01 · Earnings · neutral [SEC]
BioXcel Therapeutics issued a press release on March 27, 2026 announcing its financial results for Q4 2025 and the full year 2025, along with a business update. The filing provides standard quarterly and annual financial results without explicit beat/miss or guidance language.

Recent BTAI Form 144 Notices of Proposed Sale

2026-05-20 — — [SEC]
2026-05-20 — — [SEC]
2026-05-20 — — [SEC]

Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.

Recent Insider Filings

2026-06-18 — Rodriguez Javier (See Remarks)
2026-06-18 — Steinhart Richard I (Chief Financial Officer)
2026-06-18 — Yocca Frank (Chief Scientific Officer)
2026-06-18 — Mehta Vimal (CEO and President)
2026-05-22 — Yocca Frank (Chief Scientific Officer)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in BTAI insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

BTAI Insider Trading — FAQ

What is the latest insider trade for BTAI?: BioXcel Therapeutics, Inc. (BTAI) had 12 insider filings in the last 90 days, with the most recent on 2026-06-18. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying BTAI stock?: 0 insider purchases of BTAI were filed in the last 90 days.
How many insiders are selling BTAI stock?: 0 insider sales of BTAI were filed in the last 90 days.
Where can I see BTAI SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every BTAI SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live BTAI dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.